The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a ...

These companies have a lot more to offer than their prospects in the weight loss market.

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Late-stage study finds Roche's giredestrant shows no improvement over standard therapy in preventing cancer progression.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva ® (obinutuzumab) in adults with systemic lupus ...

Swiss pharma giant Roche has reported detailed Phase III results showing its B-cell therapy Gazyva (obinutuzumab) significantly improved outcomes for patients with systemic lupus erythematosus.

Cancer remains one of the most formidable challenges in modern medicine — but it is also one of the most dynamic frontiers of pharmaceutical innovation. Over the past decade, oncology has become the ...

A simple blood test identified women at higher risk for dementia up to 25 years before symptoms appeared. Higher levels of ...

He is the lead principal investigator of the ALLEGORY study and the lead author and he has also presented the results last Friday at SLEuro. Today, Dr. Richard Furie will take us again through the ...